Persistence of denosumab in Slovak patients with bone metastases – a prospective observational study

Česká verze

Authors: M. Porubská ¹; A. Němcová ²
Authors place of work: Onkologický ústav sv. Alžbety, Bratislava, Slovenská republika ¹; Amgen Slovakia s. r. o., Bratislava, Slovenská republika ²
Published in the journal: Klin Onkol 2023; 36(1): 54-64
Category: Původní práce
doi: https://doi.org/10.48095/ccko202354

Summary

Background: An integrated analysis of phase III trials in patients with advanced solid tumors demonstrated superiority of denosumab over zoledronic acid in preventing skeletal-related events. A drug’s clinical efficacy, however, depends on regular and continued administration (persistence); persistence in Slovak real-life is yet undetermined for denosumab in the oncology indication. Patients and methods: This was a single-arm, prospective, observational, non-interventional study in patients with bone metastases from solid tumors treated with denosumab every 4 weeks in real-world clinical practice in 5 European countries. The results of the 54 patients from Slovakia are presented here. Persistence was defined as denosumab administration at ≤ 35-day intervals over 24 or 48 weeks, respectively. Results: Previous skeletal-related events were found in 5.6% of patients. 84.8% were persistent over 24 weeks and 61.4 % over 48 weeks. The median (95% confidence interval (CI)) time to non-persistence was 306.5 days (Q1 = 151.0; Q3 = 315.0). The most frequent reason for non-persistence was delayed administration of denosumab. There was a trend towards weaker analgesics over time, with > 70% of patients not requiring any analgesics. Serum calcium remained within the normal range throughout the whole study. Adjudicated osteonecrosis of the jaw was not documented in any Slovak patient. Conclusion: Most patients received denosumab regularly once every 4 weeks over 24 weeks of treatment. Non-persistence was mainly due to delayed administration. The incidence of adverse drug reactions was in line with expectations from previous studies, osteonecrosis of the jaw did not occur in any of the patients involved in the study.

Keywords:

denosumab – bone metastases – persistence – solid tumors – observational study

Zdroje

1. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16 (4): 579–584. doi: 10.1093/annonc/mdi122.

2. Škripeková A. Prevencia skeletálnych komplikácií v protinádorovej liečbe s využitím biologickej liečby. MediNEWS 2014; 1: 45–46.

3. Špánik S, Špániková B. Súčasné odporúčania na liečbu bisfosfonátmi pri nádorových ochoreniach. Onkológia 2013; 8 (6): 368–373.

4. Križanová K. Využitie biologickej liečby v prevencii bolesti a komplikácií kostných metastáz pri nádorových ochoreniach. Paliat Med Liec Boles 2013; 6 (2): 48–52.

5. Ema.europa.eu. Súhrn charakteristických vlastností lieku. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_sk.pdf.

6. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48 (16): 3082–3092. doi: 10.1016/j.ejca.2012.08.002.

7. Pereira J, Body JJ, Gunther O et al. Cost of skeletal complications from bone metastases in six European countries. J Med Econ 2016; 19 (6): 611–618. doi: 10.3111/13696998.2016.1150852.

8. Haslbauer F, Petzer A, Safanda M et al. Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. Support Care Cancer 2020; 28 (4): 1855–1865. doi: 10.1007/s00520-019-04988-7.

9. Diel I, Ansorge S, Hohmann D et al. Denosumab and bisphosphonates persistence, compliance and switch in patients with solid tumors (ST) and bone metastases (BM). [online]. Available from: https: //www.valueinhealthjournal.com/article/S1098-3015 (17) 30702-7/ fulltext.

10. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377 (9768): 813–822. doi: 10.1016/S0140-6736 (10) 62344-6.

11. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29 (9): 1125–1132. doi: 10.1200/JCO.2010.31.3304.

12. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28 (35): 5132–5139. doi: 10.1200/JCO.2010.29.7101.